Alkermes Appoints New Chief Medical Officer
Ticker: ALKS · Form: 8-K · Filed: 2024-03-07T00:00:00.000Z
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
Related Tickers: ACAD
TL;DR
Alkermes gets a new CMO, Dr. Craig Curtis, from Acadia.
AI Summary
Alkermes plc. announced on March 5, 2024, the appointment of Dr. Craig R. Curtis as Chief Medical Officer. Dr. Curtis previously served as Executive Vice President and Chief Medical Officer at Acadia Pharmaceuticals Inc. and brings extensive experience in neuroscience drug development.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's drug development pipeline and strategic direction in the neuroscience field.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can signal shifts in strategy or development focus, introducing a degree of uncertainty.
Key Players & Entities
- Alkermes plc. (company) — Registrant
- Dr. Craig R. Curtis (person) — Newly appointed Chief Medical Officer
- Acadia Pharmaceuticals Inc. (company) — Previous employer of Dr. Curtis
FAQ
Who has been appointed as the new Chief Medical Officer of Alkermes plc?
Dr. Craig R. Curtis has been appointed as the new Chief Medical Officer of Alkermes plc.
When was this appointment announced?
The appointment was announced on March 5, 2024.
What was Dr. Curtis's previous role?
Dr. Curtis previously served as Executive Vice President and Chief Medical Officer at Acadia Pharmaceuticals Inc.
What is Dr. Curtis's area of expertise?
Dr. Curtis has extensive experience in neuroscience drug development.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 7, 2024.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 10.5 · Accepted 2024-03-07 07:09:07
Key Financial Figures
- $0.01 — on which registered Ordinary shares, $0.01 par value ALKS Nasdaq Global Select
Filing Documents
- alks-20240305.htm (8-K) — 52KB
- alks-ex99_1.htm (EX-99.1) — 19KB
- 0000950170-24-027585.txt ( ) — 195KB
- alks-20240305.xsd (EX-101.SCH) — 30KB
- alks-20240305_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 7, 2024, the Company issued a press release announcing Ms. Lurker's appointment to the Board, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. This Item 7.01 and Exhibit 99.1 furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.
01 Financial Sta tements and Exhibits
Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Press release issued by Alkermes plc dated March 7, 2024. 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: March 7, 2024 By: /s/ David J. Gaffin David J. Gaffin Secretary 3